Please assess the completion status of the following clinical trial:

Trial Title: A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria (Random 1):~* Age 16+ years~* Diagnosis of untreated (or only hydroxyurea/cyclophosphamide) acute myelogenous leukemia (AML, including myeloid sarcoma) or high-risk myelodysplasia (RAEB-2), either de novo or following an antecedent hematological disorder, or secondary to chemo-radiotherapy for other cancer~* Signed informed consent~* Adequate sampling for full cytological, cytochemical, cytogenetic and immunobiological disease characterization by revised FAB, EGIL and WHO criteria~* ECOG performance status 0-2 or reversible ECOG 3 score following intensive care of complications.~Exclusion criteria:~* Diagnosis of acute promyelocytic leukemia~* Pre-existing, uncontrolled pathology such as cardiac disease (congestive/ischemic, acute myocardial infarction within the past 3 months, untreatable arrythmias, NYHA classes III and IV), severe liver disease with serum bilirubin \>3 mg/dL and/or ALT \>3 x upper normal limit (unless attributable to AML), kidney function impairment with serum creatinine \>2 mg/dL (unless attributable to AML), and severe neuropsychiatric disorder that impairs the patient's ability to understand and sign the informed consent, or to cope with the intended treatment plan~* Known HIV positive serology~* Other active hematological or non-hematological cancers with life expectancy \<1 year~* Pregnancy (fertile women will be advised not to become pregnant while on treatment; and male patients to adopt contraceptive methods)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Remission induction arm A is with conventional chemotherapy cycle (ICE: idarubicin, standard-dose cytarabine, etoposide)
- B (Type: EXPERIMENTAL): Remission induction therapy with high-dose cytarabine sequential regimen (HD-Ara-C, idarubicin)

Based on this trial design, predict the completion outcome and termination type (if applicable).